Regulation of clot retraction by glycoprotein IIb/IIIa antagonists

Thrombosis Research

Volumn 108, Issue 2-3, 2002, Pages 181-189

  Seiffert, Dietmar ^a   Pedicord, Donna L ^a   Kieras, Cathy J ^a   He, Bokang ^a   Stern, Andrew M ^a   Billheimer, Jeffrey T ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Clot retraction; GP IIb IIIa; GP IIb IIIa antagonists; Platelets

Indexed keywords

GLYCOPROTEIN ANTAGONIST; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PROTEIN INHIBITOR; ROXIFIBAN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BLOOD CLOT RETRACTION; CONTROLLED STUDY; DEPHOSPHORYLATION; HUMAN; HUMAN CELL; PHARMACOPHORE; PRIORITY JOURNAL;

EID: 0036878172     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00395-X     Document Type: Article

References (32)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty. New Engl. J. Med. 330:1994;956-961.
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New Engl. J. Med. 336:1997;1689-1696.
3. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 349:1997;1429-1435.
4. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl. J. Med. 338:1998;1488-1497.
5. Inhibition of platelet glycoprotein IIb/IIIa with eptifibratide in patients with acute coronary syndromes. New Engl. J. Med. 339:1998;436-443.
6. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess the safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockage. Lancet. 352:1998;87-92.
7. Cannon C.P. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin. Cardiol. 23(Suppl. VI):2000;14-17.
8. Newby L.K., McGuire D.K. Oral platelet glycoprotein IIb/IIIa inhibitors. Curr. Cardiol. Rep. 2:2000;372-377.
9. Chew D.P., Moliterno D.J. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J. Am. Coll. Cardiol. 36:2000;2028-2035.
10. Phillips D.R., Charo I.F., Parise L.V., Fitzgerald L.A. The platelet membrane glycoprotein IIb/IIIa complex. Blood. 71:1988;831-843.
11. Niiya K., Hodson E., Bader R., Byers-Ward V., Koziol J.A., Plow E.F.et al. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood. 70:1987;475-483.
12. Wagner C.L., Mascelli M.A., Neblock D.S., Weisman H.F., Coller B.S., Jordan R.E. Analysis of GP IIb/IIIa receptor number by quantification of c7E3 binding to human platelets. Blood. 88:1996;907-914.
13. Gogstad G.O., Hagen I., Korsmo R., Solum N.O. Characterization of the proteins of isolated human platelet alpha granules. Evidence for a separate alpha-granule pool of the glycoprotein IIb and IIIa. Biochim. Biophys. Acta. 670:1981;150-162.
14. Woods V.L., Wolff L.E., Keller D.M. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. J. Biol. Chem. 261:1986;15242-15251.
15. Plow E.F., Shattil S.J. Integrin IIb/IIIa and platelet aggregation. Colman R.W., Hirsh J., Marder V.J., Clowes A.W., George J.N. Hemostasis and Thrombosis. 2000;479-492 Lippincott Williams & Wilkins, Philadelphia.
16. Shattil S.J., Kashiwagi H., Pampori N. Integrin signaling: the platelet paradigm. Blood. 91:1998;2645-2657.
17. Clark E.A., Brugge J.S. Tyrosine phosphorylation. Authi K.S., Watson S.P. Platelets. 1995;199-216 IRL Press, Oxford.
18. Abrams C.S., Brass L.F. Platelet signal transduction. Colman R.W., Hirsh J., Marder V.J., Clowes A.W., George J.N. Hemostasis and Thrombosis. 2000;540-541 Lippincott Williams & Wilkins, Philadelphia.
19. Cohen I., Burk D.L., White J.G. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb-IIIa complex on the development of clot tension. Blood. 91:1989;2645-2657.
20. Carr M.E., Carr S.L., Hantgan R.R., Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb. Haemost. 82:1995;468-480.
21. Jennings L.L.K., White M.M., Mandrell T.D. Interspecies comparison of platelet aggregation, LIB expression and clot retraction: observed differences in GPIIb-IIIa functional activity. Thromb. Haemost. 74:1995;1551-1556.
22. Mousa S.A., Khurana S., Forsythe M.S. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography. Arterioscler. Thromb. Vasc. Biol. 20:2000;1162-1167.
23. Cohen K., Gerrard J.M., White J.G. Ultrastructure of clots during isometric contraction. J. Cell Biol. 93:1982;775-783.
24. Osdoit S., Rosa J.-P. Fibrin clot retraction by human platelets correlates with GP IIb/IIIa integrin-dependent protein tyrosine dephosphorylation. J. Biol. Chem. 276:2001;6703-6710.
25. Olson R.E., Sielecki T.M., Wityak J., Pinto D.J., Batt D.G., Frietze W.E.et al. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. J. Med. Chem. 42:1999;1178-1192.
26. Mousa S.A., Bozarth J., Naik U., Slee A. Platelet GP IIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Br. J. Pharmacol. 133:2001;331-336.
27. Mousa S.A., Bozarth J., Lorelli W., Forsythe M., Thoolen M., Slee A.et al. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GP IIb/IIIa antagonist: comparative platelet binding profiles with c7E3. J. Pharmacol. Exp. Ther. 286:1988;1277-1284.
28. Mousa S.A., Bozarth J., Lorelli W., Forsythe M., Thoolen M., Slee A.et al. Discovery of novel orally active non-peptide platelet GP IIb/IIIa receptor antagonists, DMP754: comparative platelet binding profile with c7E3. J. Pharmacol. Exp. Ther. 286:1998;1277-1284.
29. Marguerie G.A., Edgington T.S., Plow E.F. Interaction of fibrinogen with its platelet receptor is part of a multistep reaction in ADP-induced platelet aggregation. J. Biol. Chem. 255:1980;154-161.
30. Marguerie G.A., Plow E.F. Interaction of fibrinogen with its platelet receptor: kinetics and effect of pH and temperature. Biochemistry. 20:1981;1074-1080.
31. Peerschke E.I.B., Wainer J.A. Examination of irreversible platelet-fibrinogen interactions. Am. J. Physiol. 248:1985;C466-C472.
32. Hantgan R.R., Mousa S.A. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb. Res. 89:1998;271-279.